Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

被引：0

作者：

Manabu Futamura

Takahiro Nakayama

Tetsuhiro Yoshinami

Chiya Oshiro

Mikiya Ishihara

Midori Morita

Akira Watanabe

Azusa Tanigichi

Masami Tsukabe

Masafumi Shimoda

Kanae Nitta

Yoko Chihara

Hiroyuki Yasojima

Yoshimi Ouchi

Yoshihisa Tokumaru

Norikazu Masuda

机构：

[1] Gifu University Hospital,Department of Breast Surgery

[2] Osaka International Cancer Institute,Department of Breast and Endocrine Surgery

[3] Osaka University Graduate School of Medicine,Department of Breast and Endocrine Surgery

[4] Kaizuka City Hospital,Department of Breast Surgery

[5] Mie University Hospital Cancer Center,Division of Endocrine and Breast Surgery

[6] Kyoto Prefectural University of Medicine,Department of Breast and Endocrine Surgery

[7] Osaka Police Hospital,Breast and Endocrine Surgery

[8] Otemae Hospital,Department of Breast Surgery

[9] Itami City Hospital,Department of Surgery Breast Oncology

[10] NHO Osaka National Hospital,Department of Breast Surgery

[11] Saiseikai Shiga Hospital,Department of Breast and Endocrine Surgery

[12] Nagoya University Graduate School of Medicine,undefined

来源：

Breast Cancer | 2023年 / 30卷

关键词：

Luminal; Metastatic breast cancer; CDK4/6 inhibitor; Resistant; NOLUS;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：943 / 951

页数：8

共 168 条

[1]

Sørlie T(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869-10874

[2]

Perou CM(2012)A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen Clin Cancer Res 18 4465-4472

[3]

Tibshirani R(2019)Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials Cancers (Basel). 11 1661-138

[4]

Aas T(2016)Targeting CDK4/6 in patients with cancer Cancer Treat Rev 45 129-1936

[5]

Geisler S(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-219

[6]

Johnsen H(2015)Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373 209-3646

[7]

Chia SK(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 35 3638-2884

[8]

Bramwell VH(2017)MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 35 2875-1936

[9]

Tu D(2018)Overall survival with palbociclib and fulvestrant in advanced breast cancer N Engl J Med 379 1926-124

[10]

Shepherd LE(2020)The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial JAMA Oncol 6 116-273

← 1 2 3 4 5 6 7 8 9 10 →